vaccines - all results

Treatment	Number of studies	clinical deterioration	clinical improvement	deaths	viral clearance
mRNA vaccine	66 studies[1]	-	-	0.50 [0.11 ; 2.28], 2 RCTs, I2=0% inconclusive result	-
Non replicating viral vector	34 studies[2]	-	-	0.19 [0.06 ; 0.64], 2 RCTs, I2=0% moderate degree of certainty	-
first booster dose	20 studies[3]	-	-	0.13 [0.08 ; 0.24], 6 studies, I2=78% high degree of certainty	-
Inactivated virus vaccine	12 studies[4]	-	-	0.20 [0.14 ; 0.28], 1 study, I2=0% certainty unassessable	-
second booster dose	7 studies[5]	-	-	0.22 [0.17 ; 0.28], 1 study, I2=0% certainty unassessable	-
protein subunit vaccine	4 studies[6]	-	-	-	-
complete primary vaccine series	1 study[7]	0.45 [0.34 ; 0.60], 3 studies, I2=66% certainty unassessable	-	0.16 [0.06 ; 0.41], 5 studies, I2=79% high degree of certainty	-
heterologous prime-boost	1 study[8]	-	-	-	-

Notes

[1]Haas, 2021 (emergency) ; BNT162b2 phase 3 (C4591001, Polack), 2020 (NCT04368728) ; COVE Moderna/NIH phase 3 (study 301), 2020 (NCT04470427) ; Moderna study 201 100µg, 2020 (NCT04405076) ; McConeghy, 2022 () ; Nguyen, 2022 () ; Amit, 2021 () ; Dagan, 2021 () ; SIREN (HW england), 2021 (ISRCTN11041050) ; Tang, 2021 () ; Thompson, 2021 () ; Agur, 0 () ; Scotland cohort, 0 () ; Shemer, 2021 () ; Accorsi, 2022 () ; Thompson -VISIOn Network (omicron), 2022 () ; Husby (Moderna), 2021 () ; Husby (pfizer), 2021 () ; Patone, 2021 () ; Shasha, 2021 () ; Abu-Raddad, 2022 () ; Kirsebom (UKHSA), 2022 () ; Angel, 2021 () ; Barda, 2021 () ; Bernal (PHE, 19th February 2021), 2021 () ; Bjork, 2021 () ; Burn (Pfizer), 2021 () ; Chodcik, 2021 () ; Edward (pfizer), 2021 () ; EPI-PHARE, 2021 () ; Goldberg, 2021 () ; Haas, 2021 () ; Heymann, 2021 () ; Klein, 2021 () ; Mayo Clinic (Puranik), 2021 () ; McMurry, 2021 () ; Moderna delta VOC press realease, 2021 () ; Nanduri, 2021 () ; Pawlowski, 2021 () ; Shibli, 2021 () ; Tartof, 2021 (NCT04848584) ; Weekes, 2021 () ; Tande, 0 () ; Lauring, 2022 () ; Patalon, 2022 () ; Southern California (Tseng) - delta, 2022 () ; Southern California (Tseng) - omicron, 2022 () ; Tenforde, 2022 () ; Abu-Raddad, 2021 () ; Chung, 2021 () ; England (Andrews), 2021 () ; Qatar (Tang), 2021 () ; South Africa (Discovery Health, Collie), 2021 () ; Tenforde, 2021 () ; Wan, 2021 () ; Aleman, 2021 () ; Benotmane, 2021 () ; Boyarsky, 2021 () ; Palich, 2021 () ; Rozen-Zvi, 2021 () ; Yanay, 2021 () ; Zadok, 2021 ()

[2]Asano, 2022 (NCT04568031) ; Com-COV2, 2022 (ISRCTN 27841311) ; Li J, 2022 (NCT04892459) ; AstraZeneca phase 3 US (D8110C00001), 2021 (NCT04516746) ; AstraZeneca phase 3 US (D8110C00001) 6 month follow up, 2021 (NCT04516746) ; Com-COV, 2021 (ISRCTN69254139) ; Fengcai, 2021 (NCT04566770) ; Kulkarni, 2021 (CTRI/2020/08/027170) ; Reindl-Schwaighofer, 2021 () ; Sadoff, 2021 (NCT04436276) ;

Downloaded from www.metaEvidence.org

AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)$_{safety}$, 2020(); $CanSinophase2(Zhu)$, 2020($NCT04341389$); $ChAdOx1phase3(AstraZeneca)$, 2020($NCT04400838$); $RESIST(SputnikVGam$
$PHARE)$, 2022(); $EPIPHARE(Janssen)$, 2022(); $EPIPHARE(Vaxzevria)$, 2022(); $Hippisley-Cox$, 2021(); $Husby(Astra)$, 2021(); $Husby(janssen)$, 2021(); $Patone$, 2021(); $Simpson(ChAdOx1)$, 2021(); $Nabirova$

[3]C4591031- first boost, 2021 (NCT04955626) ; Hall, 2021 (NCT04885907) ; Pfizer/BioNTech Booster study, 2021 (NCT04713553) ; COVI3, 2022 () ; McConeghy, 2022 () ; Kislaya, 2022 () ; Bar-On, 2021 () ; Accorsi, 2022 () ; Tan, 2022 () ; Abu-Raddad, 2022 () ; Arbel, 2021 () ; Barda, 2021 () ; Mattiuzzi, 2022 () ; Ontario (Buchan), 2022 () ; Patalon, 2022 () ; Tenforde, 2022 () ; England (Andrews), 2021 () ; Patalon, 2021 () ; Sisonke 2 (booster), 2021 (NCT05148845)

[4]PROFISCOV (SinoVac Brazil), 2021 (NCT04456595) ; Sinopharm Wuhan Vero cell, 2021 (NCT04510207) ; Xia (66), 2020 (ChiCTR2000032459) ; CoronaVac Indonesia, 0 (NCT04508075) ; Sinovac Turkish Trial, 0 (NCT04582344) ; Ashmawy, 2022 () ; Faria, 2021 () ; Chile study (Aaros), 0 () ; Hitchings, 2021 () ; Li, 2021 () ; Wan, 2021 () ; Bonfa, 2021 (NCT04754698)

[5]Bar-On, 2022 () ; Cohen, 2022 () ; Arbel / Magen, 2022 () ; Regev-Yochay (Comirnaty), 2022 (NCT05231005) ; Regev-Yochay (Spikevax), 2022 (NCT05231005)

[6]Novavax phase 2 South Africa (2019nCoV-501), 2021 (NCT04533399) ; Novavax phase 3 UK (2019nCoV-302), 2021 (NCT04583995) ; Novavax PREVEND-19 phase 3 US (2019nCoV-301), 2021 (NCT04611802) ; Keech, 2020 (NCT04368988)

[7]South Africa (Discovery Health, Collie), 2021 ()

[8]CombiVacS, 2021 (NCT04860739)

Downloaded from www.metaEvidence.org